CHO/CERT Cell Lines for Enhanced Protein Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to enhance protein secretion in mammalian cells for biopharmaceutical production face challenges due to limited understanding of regulatory mechanisms and often result in growth inhibition or apoptotic responses, leading to suboptimal secretion and yield.
Innovation Solution
Development of CHO/CERT 2.20 and CHO/CERT 2.41 cell lines through overexpression of the ceramide transfer protein (CERT) mutant S132A, which improves secretory capacity and growth characteristics, thereby enhancing recombinant protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the secretory capacity of host cells is enhanced through overexpression of secretory pathway components, then protein secretion is improved, but cell growth is inhibited or apoptotic responses occur
Solution Approach 1:
The patent applies parameter changes by modifying the CERT protein at the molecular level (S132A mutation) to alter its function. This specific amino acid substitution changes the protein's interaction properties, enabling enhanced ceramide transfer activity without triggering the harmful cellular responses that occur with other secretory pathway modifications. The parameter change at the protein level resolves the contradiction between improved secretion and maintained cell health.
Solution Approach 2:
The CERT protein acts as an intermediary component in the secretory pathway, facilitating ceramide transfer from the endoplasmic reticulum to the Golgi apparatus. By enhancing CERT function through the S132A mutation, the patent improves protein secretion indirectly by optimizing this intermediate transport step, rather than directly manipulating the secretory output. This intermediary approach allows secretion enhancement without the harmful effects of direct secretory pathway overactivation.
2Productivity
If mRNA level of product gene is enhanced to increase productivity, then protein synthesis capacity is improved, but intracellular accumulation of protein product occurs due to overload of transport machinery
Solution Approach 1:
The patent applies preliminary action by enhancing the CERT-mediated ceramide transfer function before protein synthesis and secretion occur. By pre-optimizing the lipid transport machinery (ceramide transfer) that is required upstream of protein secretion, the cell is prepared to handle increased protein synthesis loads without developing bottlenecks. This preliminary enhancement of transport capacity prevents the intracellular accumulation that would otherwise result from overwhelming the secretory pathway.
Solution Approach 2:
The patent extracts and specifically targets the CERT protein function from the complex secretory pathway, isolating this single critical transport step for enhancement. By focusing on extracting and optimizing this specific ceramide transfer function rather than broadly enhancing all secretory components, the patent achieves improved protein secretion capacity without causing the systemic overload and intracellular accumulation that results from comprehensive secretory pathway activation.
Data Source
AI summary
The invention concerns the field of cell culture technology. The invention describes production host cell lines comprising vector constructs comprising a CERT S132 A expression cassette. Those cell lines have improved growth characteristics and high CERT S132A expression levels. The invention especially concerns two cell lines deposited with the DSMZ under the number DSM ACC2989 (CHO/CERT 2.20) and DSM AC-C2990 (CHO/CERT 2.41). The invention further concerns a method of generating such preferred production host cells and a method of producing proteins using the two cell lines deposited with the DSMZ under the number DSM ACC2989 (CHO/CERT 2.20) and DSM ACC2990 (CHO/CERT 2.41).